Rani Therapeutics HoldingsRANI -1.78%32 PB Ratio is 2.64 as of Jun. 30, 2026, which is 8% below its 10-year median of 2.88. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,229 Biotechnology companies, Rani Therapeutics Holdings ranks better than 52.89% on this metric.
The historical rank and industry rank for Rani Therapeutics Holdings's PB Ratio or its related term are showing as below:
RANI'
s PB Ratio Range Over the Past 10 Years
Min: 0.64 Med: 2.88 Max: 30.83
Current: 2.59
During the past 7 years, Rani Therapeutics Holdings's highest PB Ratio was 30.83. The lowest was 0.64. And the median was 2.88.
RANI's PB Ratio is ranked better than 52.89% of 1229
companies
in the Biotechnology industry
Industry Median: 2.86
vs RANI: 2.59
During the past 3 years, the average Book Value Per Share Growth Rate was -38.60% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Rani Therapeutics Holdings was -38.60% per year. The lowest was -70.80% per year. And the median was -54.70% per year.
Back to Basics: PB Ratio
Rani Therapeutics Holdings (NAS:RANI) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Rani Therapeutics Holdings PB Ratio Related Terms
Rani Therapeutics Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rani Therapeutics Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rani Therapeutics Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Rani Therapeutics Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Rani Therapeutics Holdings (RANI) has a PB Ratio of 2.64 as of Jun. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rani Therapeutics Holdings and its competitors. This is near median its historical median of 2.88. Over the past decade, Rani Therapeutics Holdings' PB Ratio has ranged from 0.64 to 30.83. According to the industry distribution chart, Rani Therapeutics Holdings ranks #579 out of 1229 companies in the Biotechnology industry, placing it in the top 47.1%.
Is Rani Therapeutics Holdings' PB Ratio too high?
Rani Therapeutics Holdings' current PB Ratio of 2.64 is near median its 10-year median of 2.88. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 30.83. The Biotechnology industry median PB Ratio is 2.86. Rani Therapeutics Holdings' value of 2.64 is 7.7% below this industry median. Based on the distribution chart, Rani Therapeutics Holdings ranks #579 out of 1229 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' PB Ratio compare to IBIO and RNTX?
According to the Biotechnology industry distribution chart, Rani Therapeutics Holdings ranks #579 out of 1229 companies for PB Ratio. This puts Rani Therapeutics Holdings in the upper half of its industry. The industry median PB Ratio is 2.86. Rani Therapeutics Holdings' value of 2.64 is 7.7% below this benchmark. Historically, Rani Therapeutics Holdings' own PB Ratio has ranged from 0.64 to 30.83 over the past decade. While the company's 10-year median is 2.88 vs. the industry median of 2.86, Rani Therapeutics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.86, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rani Therapeutics Holdings's current PB Ratio of 2.64 is 7.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rani Therapeutics Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rani Therapeutics Holdings's current PB Ratio is 2.64, which is near median its own 10-year median of 2.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current PB Ratio of 2.64. The current PB Ratio is 2.64, which is near median its 10-year median of 2.88 and 7.7% below the Biotechnology industry median of 2.86. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current PB Ratio is 2.64 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score
Get the complete analysis for RANI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RANI has been successfully added to your 
